Innovation in the development of nanomedicines

CARLINA Technologies is a biopharmaceutical company specialized in the development of nanomedicines utilizing innovative non-denaturing drug delivery technologies for therapeutic proteins, peptides and other types
of drugs.

The company develops controlled-release pharmaceutical versions of drugs capable of targeting them to their site of action. This results in increased efficacy and safety of treatments leading to improved patients’ compliance and quality of life.


The company based in Angers (France) was founded in 2010 by Olivier Meyer and Pr. Jean-Pierre Benoît, President and CEO, and Chairman of the Scientific Advisory Board, respectively.

Olivier Meyer

During his more than 15 years of professional experience, Olivier Meyer held several managing and executive R&D and corporate positions in biotechnology and pharmaceutical companies both in France and North America, among others, at Transgene and AstraZeneca. Dr Meyer obtained his Ph.D. in Pharmaceutical Technologies from the University of Paris XI in 1995 and completed his post-doctoral fellowship at UC San Francisco in the group of Pr Demetrios Papahadjopoulos, a pioneer in the development of liposomal drugs (e.g. Doxil®).

Jean-Pierre Benoît

Jean-Pierre Benoît, Pharm.D. Ph.D., is Professor at the University of Angers in Pharmaceutical Sciences and Director of the Laboratory of Bio-inspired Micro and Nanomedicines (Inserm U1066). He is the co-inventor of the drug delivery technologies exploited by CARLINA Technologies. Among the numerous distinctions that Pr Benoît has received during his more than 20 years of academic career, he has recently been attributed the prestigious International Pharmaceutical Federation Award and the Notorious Award of the French Academy of Pharmacy.




While modern genomic and proteomic technology enables rapid screening of novel proteins and peptides as potential drug candidates, design of delivery systems for these biologics remains challenging.Today therapeutic proteins are used to relieve patients suffering from many diseases, including:

  • Cancer (monoclonal antibodies, interferons)
  • Cardiovascular diseases, cystic fibrosis, Gaucher’s disease (enzymes, blood factors)
  • Diabetes (insulin)
  • Anaemia (erythropoietin)
  • Haemophilia (blood clotting factors)
  • Wound healing (Growth factors)

Proteins are highly organized, complex structures that must maintain structural and chemical integrity to function properly. Many manufacturing methods can jeopardize this by exposing proteins to potentially damaging conditions, such as aqueous/organic interfaces, elevated temperatures, vigorous agitation, hydrophobic surfaces, and detergents. Moreover, upon administration the solid protein becomes hydrated and exposed to physiological temperature within the delivery device for long periods of time. At this stage, the polymer matrix microenvironment and the products of polymer degradation can also reduce protein stability. Thus, proteins are exposed to a variety of stresses over the entire life of a controlled-release system, including formulation, long-term storage, and release in vivo.

PEPTIDOTS* technology represents a unique and innovative non-denaturating protein encapsulation process providing :

  • Encapsulation processes preserving native protein structure and activity
  • Efficient protection against enzymatic degradation
  • Low viscosity solutions of highly concentrated proteins for achievable therapeutic dosage
  • Procedures not requiring the use of stabilizers
  • Biocompatibility / Safety
  • High encapsulation efficiency
  • Prolonged-release of proteins/peptides

Corresponding manufacturing process uses two mains steps :

Reversible nanoprecipitation of protein

Step 1 : Reversible nanoprecipitation of protein
Protein nanoprecipitates Ø ~ 150nm

Microencapsulation of nanoprecipitates in polymeric matrix

Step 2 : Microencapsulation of nanoprecipitates in polymeric matrix
Protein containing microspheres Ø ~ 60µm

R & D Services

While developing its proprietary micro and nanomedicines, CARLINA Technologies also provides high quality R&D formulation development services to the pharmaceutical, biotechnology and veterinary industries including:

  • Pre-formulation
  • Formulation
  • Process manufacturing
  • Preclinical batch production
  • Scale-up and technology transfer
  • Analytical method development
  • Stability studies

If your drug candidate requires improved solubilization, stability, protection, pharmacokinetics, bioavailability, targeting, controlled delivery, safety, whatever the administration route used, CARLINA Technologies will help you to design, develop and manufacture the most unique and appropriate delivery system according to the nature of your active ingredient without affecting its chemical integrity.

Thanks to the outstanding know-how of its R&D team, CARLINA technologies can use all available proprietary, as well as off-patent, drug delivery systems including:

  • SOLUDOTS* (lipid nanocapsules)
  • Liposomes
  • Micelles
  • Microspheres
  • Micro & nanoemulsions
  • Hydrogels
Industrial objectives

For each project, CARLINA Technologies takes industrial, economic or commercial requirements into consideration according to specific products and corresponding therapeutic applications. CARLINA’s expertise in project management allows rigorous development phase evaluation and control.

Sense of innovation

The creativity of CARLINA Technologies results from the complementary of its team, acquired experience from diversified and complex projects as well as advanced competitive intelligence knowledge. This is the basis for bringing unique solutions and original innovation and valorization axes proposed to our clients and partners.

An international recognized scientific expertise

Each study benefits from high level scientific input from international, well recognized, experts in the field of drug delivery, as well as high quality specialized analytical equipment and methodologies (high performance chromatography, electrophoretic mobility, dynamic light scattering, electron microscopy…)

Process manufacturing, upscaling, and industrial technology transfer

Following early laboratory scale drug encapsulation feasibility studies, CARLINA technologies’ manufacturing processes transposition for industrial scales production can rapidly be evaluated and validated.


CARLINA Technologies has currently two product candidates under development:



PEPTIDOTS-insulin is a prolonged-release formulation of insulin aiming at better controlling the basal glycaemia of patients with diabetes over several days following single subcutaneous injection.

This product candidate is entering its preclinical development phase. In vivo proof-of-concept in rats has already shown a 3-fold increase in duration of action of native insulin correlating with improved pharmacokinetics.

Over the next 15 years, the WHO predicts that worldwide insulin sales will grow from US$12B to US$54B, doubling in the US, tripling in the EU, and expending 12 fold in the ROW. In 2030, diabetes patients will represent more than 10% of the whole world population (500 million people).


PEPTIDOTS-somatotropin is a sustained-release pharmaceutical form of growth hormone aiming at better treating growth hormone deficiency improving treatment outcomes.

This product candidate has entered its lead optimization development phase.  Optimized candidate will aim at releasing growth hormone over several weeks following single subcutaneous administration.

The global market for Human Growth Hormone drugs is forecast to reach US$4.7B by the year 2018. Major factors driving future growth in the market include high prevalence of growth hormone deficiency and expanding indications of growth hormones.

CARLINA Technologies provides out-licensing opportunities to pharmaceutical industry partners to co-develop its product candidates.

*Trademark pending

Contact us

Carlina Technologies
22, rue Roger Amsler
49100 Angers
+33 241 249 282